Table 2 Antiemetic regimen
5HT3RA | N(%) | Dexamethasone | N(%) | |||
|---|---|---|---|---|---|---|
FOLFOX | Palonosetron | Day1 | 60 (75.9) | Day1 | 4 (6.7) | |
Day1–3 | 56 (93.3) | |||||
1st generation 5HT3RA | Day1 | 19 (24.1) | Day1 | 7 (36.8) | ||
Day1–3 | 12 (63.2) | |||||
CAPOX | palonosetron | Day1 | 72 (92.3) | Day1 | 2 (2.8) | |
Day1–3 | 70 (97.2) | |||||
1st generation 5HT3RA | Day1 | 6 (7.7) | Day1 | 2 (33.3) | ||
Day1–3 | 4 (66.7) | |||||
CBDCA + ETP | 1st generation 5HT3RA | Day1 | 34 (100.0) | Day1–3 | 34 (100.0) | |
CBDCA + PTX | 1st generation 5HT3RA | Day1 | 58 (100.0) | Day1 | 57 (98.3) | |
(Lung Cancer) | Day1–3 | 1 (1.7) | ||||
CBDCA + PEM | palonosetron | Day1 | 9 (18.7) | Day1 | 7 (77.8) | |
Day1–3 | 1 (11.1) | |||||
Day1–4 | 1 (11.1) | |||||
1st generation 5HT3RA | Day1 | 39 (81.3) | Day1 | 31 (79.5) | ||
Day1–2 | 1 (2.6) | |||||
Day1–3 | 7 (17.9) | |||||
CBDCA + PTX | palonosetron | Day1 | 1 (2.2) | Day1 | 1 (2.2) | |
(Ovarian Cancer) | 1st generation 5HT3RA | Day1 | 42 | 44 (97.8) | Day1 | 33 (73.3) |
Day1–3 | 2 | Day1–3 | 11 (24.4) | |||
DTX + CPA | palonosetron | Day1 | 11 (27.5) | Day1 | 5 (45.5) | |
Day1–3 | 1 (9.1) | |||||
Day1–4 | 5 (45.5) | |||||
1st generation 5HT3RA | Day1 | 29 (72.5) | Day1 | 1 (3.4) | ||
Day1–3 | 1 (3.4) | |||||
Day1–4 | 27 (93.1) | |||||